SCHEMBL440935

SCHEMBL440935

O=S(=O)(O)c1c(Cl)cccc1Cl

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.44
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
ATM Q13315 2/20 0.42
CNR1 P21554 1/20 0.41
SLC1A3 P43003 1/20 0.41
SLC1A2 P43004 1/20 0.41
TSHR P16473 4/20 0.40
AKR1B1 P15121 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
GAA P10253 1/20 0.40
POLB P06746 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP1A2 P05177 1/20 0.39
CYP2A6 P11509 1/20 0.39
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27552065 0.97 ALDH1A1 (0.42) ALDH1A1KMT2AMEN1TDP1ATM
SCHEMBL149755 0.88 TTR (0.44) ALDH1A1KMT2AMEN1TDP1ATM
SCHEMBL2844949 0.88 NSD2 (0.39) ALDH1A1KMT2AMEN1TDP1ATM
SCHEMBL5728040 0.86 TSHR (0.48) ALDH1A1KMT2AMEN1TDP1ATM
SCHEMBL4635992 0.84 SLC40A1 (0.43) ALDH1A1KMT2AMEN1TDP1ATM
SCHEMBL10296112 0.84 PKM (0.47) ALDH1A1KMT2AMEN1TDP1ATM
SCHEMBL6939244 0.84 TTR (0.46) ALDH1A1KMT2AMEN1TDP1ATM
SCHEMBL10955365 0.83 TDP1 (0.50) ALDH1A1KMT2AMEN1TDP1ATM
Hydrochloric Acid SCHEMBL4303872 0.83 SLC40A1 (0.42) ALDH1A1KMT2AMEN1TDP1ATM
SCHEMBL8206228 0.81 KMT2A (0.36) ALDH1A1KMT2AMEN1TDP1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8110571-B2 Tyrosine kinase inhibitors; antiproliferation agents; metabolism diseases; antiallergens; central nervous system disorders; vision and skin disorders; antiarthritic agents AVENTIS PHARMA S.A. (FR) 2012-02-07 US claimed
EP-1934187-A1 NOVEL BENZIMIDAZOLE AND BENZOTHIAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, USE THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS C-MET INHIBITORS Aventis Pharma S.A. (FR) 2008-06-25 EP claimed
WO-2007036630-A1 NOVEL BENZIMIDAZOLE AND BENZOTHIAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, USE THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS C-MET INHIBITORS AVENTIS PHARMA S.A. (FR) 2007-04-05 WO claimed
US-20060094880-A9 Synthetic process for trans-aminocyclohexyl ether compounds BARRETT ANTHONY G M 2006-05-04 US claimed
WO-2005016242-A2 SYNTHETIC PROCESS FOR TRANS-AMINOCYCLOHEXYL ETHER COMPOUNDS CARDIOME PHARMA CORP. (CA) 2005-02-24 WO claimed
US-20050038256-A1 Synthetic process for trans-aminocyclohexyl ether compounds CARDIOME PHARMA CORP. (CA) 2005-02-17 US claimed
US-20250020997-A1 PHOTORESIST COMPOSITIONS AND METHODS OF MANUFACTURING INTEGRATED CIRCUIT DEVICES USING THE SAME SAMSUNG ELECTRONICS CO., LTD. (KR) 2025-01-16 US disclosed
CN-117642422-A Structure for reducing antibody-lipase binding 基因泰克公司 2024-03-01 CN disclosed
US-20230176481-A1 FILM-FORMING COMPOSITION NISSAN CHEMICAL CORPORATION (JP) 2023-06-08 US disclosed
US-9586899-B2 Synthetic process for aminocyclohexyl ether compounds CARDIOME PHARMA CORP. (CA) 2017-03-07 US disclosed
US-20150336887-A1 SYNTHETIC PROCESS FOR AMINOCYCLOHEXYL ETHER COMPOUNDS CORREVIO CANADA CORP. (CA) 2015-11-26 US disclosed
US-9115081-B2 Synthetic process for aminocyclohexyl ether compounds CARDIOME PHARMA CORP. (CA) 2015-08-25 US disclosed
EP-1676835-B1 PROCESS FOR PRODUCING TRIARYLSULFONIUM SALT WAKO PURE CHEM IND LTD (JP) 2014-12-10 EP disclosed
EP-0385874-A1 Functionalisation at position (n+1) of aryl derivatives disubstituted at position n and (n+2) RHONE-POULENC CHIMIE (FR) 1990-09-05 EP disclosed
EP-0224292-B1 PROCESS FOR THE PREPARATION OF ORGANIC ISOCYANATES SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1990-04-11 EP disclosed
US-4851094-A OXIDIZING A THIOUREA WITH HYDROGEN PEROXIDE USING A MOLYBDENUM -CONTAINING CATALYST MCNEILAB, INC. (US) 1989-07-25 US disclosed
US-4781866-A Process for producing amidine sulfonic acid intermediates for guanidines MCNEILAB, INC. (US) 1988-11-01 US disclosed
EP-0248586-A2 Process for producing amidine sulfonic acid intermediates for guanidines McNeilab, Inc. (US) 1987-12-09 EP disclosed
EP-0224292-A1 Process for the preparation of organic isocyanates SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1987-06-03 EP disclosed
US-4656291-A OXIDIZING THIOUREA DERIVATIVE WITH HYDROGEN PEROXIDE IN PRESENCE OF MOLYBDENUM CATALYST MCNEILAB, INC. (US) 1987-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094880-A9 Synthetic process for trans-aminocyclohexyl ether compounds AKR1C3, CBR1, CBR3 ALDH1A1 1484/4885KMT2A 3897/4885MEN1 1794/4885
US-20050038256-A1 Synthetic process for trans-aminocyclohexyl ether compounds AKR1C3, CBR1, CBR3 ALDH1A1 1484/4885KMT2A 3897/4885MEN1 1794/4885
US-20150336887-A1 SYNTHETIC PROCESS FOR AMINOCYCLOHEXYL ETHER COMPOUNDS DDC, PAICS, CYP4F2 ALDH1A1 3196/4885KMT2A 2038/4885MEN1 1043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.